Pharmaceuticals News and Research

RSS

IGI Laboratories net revenues increase 101% to $3.7M in first quarter 2013

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the first quarter ended March 31, 2013.

26 Apr 2013

HHS global health official discusses tobacco-, drug patent-related trade negotiations

Inside U.S. Trade features an interview with HHS Assistant Secretary forAffairs Nils Daulaire, who discusses how "the department is playing a larger role than ever before in the development of U.S. trade policy, including on sensitive issues in the Trans-Pacific Partnership (TPP) negotiations like a draft proposal for a tobacco-specific 'safe harbor' and the U.S. stance on issues related to intellectual property protections for pharmaceuticals," according to the publication.

25 Apr 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

U.S. files suit against Novartis in alleged kickback scheme

The suit accuses the drugmaker of giving pharmacies discounts and rebates to promote the use of the drug Myfortic.

25 Apr 2013

Viewpoints: Physician payment sunshine rules may not stop conflicts of interest; Support wanes for health law

The federal Center for Medicare & Medicaid Services recently announced final regulations for the Physician Payment Sunshine Act, which requires pharmaceutical and medical-device companies to disclose payments they make to doctors, hospitals and other health-care providers.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

First Edition: April 24, 2013

Today's headlines include stories about the health law's implementation as well as health policy developments from Capitol Hill.

24 Apr 2013

Advaita selected to participate in Michigan I-Corps program starting May 2013

Advaita, a Plymouth, MI biotechnology startup company spun out from Wayne State University, is one of 25 companies selected to participate in the new Michigan I-Corps program starting May 2013.

24 Apr 2013

South Africa aims to close drug patent loophole that allows for 'ever-greening'

"South Africa plans to overhaul its intellectual property laws to improve access to cheaper medicines by making it harder for pharmaceutical firms to register and roll-over patents for drugs, a senior official said on Monday," Reuters reports.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.

23 Apr 2013

U.S. Drug Enforcement Administration to hold national drug take-back day this weekend

On April 27, the U.S. Drug Enforcement Administration will be running a national drug take-back day. It is an opportunity for everyone to safely remove unwanted, unused, or expired medication from medicine cabinets.

23 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

The University of Glasgow is set to boost its contribution to global medical research and the Scottish economy following the announcement of funding to build a major research centre.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Pharmaceuticals News and Research

IGI Laboratories net revenues increase 101% to $3.7M in first quarter 2013

HHS global health official discusses tobacco-, drug patent-related trade negotiations

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

U.S. files suit against Novartis in alleged kickback scheme

Viewpoints: Physician payment sunshine rules may not stop conflicts of interest; Support wanes for health law

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

First Edition: April 24, 2013

Advaita selected to participate in Michigan I-Corps program starting May 2013

South Africa aims to close drug patent loophole that allows for 'ever-greening'

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

U.S. Drug Enforcement Administration to hold national drug take-back day this weekend

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence